Precigen, Inc. (NASDAQ: PGEN) released its Q4 and full-year 2025 results on March 25, 2026. The narrative is shifting from a research-heavy biotech to a commercial-stage player as it nears a critical FDA milestone for its lead gene therapy.
Earnings Results
| Metric | Q4 2025 | Estimate | Result | FY 2025 | Estimate | Result |
| Revenue | $4.57 Million | $8.29 Million | Miss | $9.7 Million | $8.29 Million | Beat |
| EPS (Non-GAAP) | -$0.01 | -$0.10 | Beat | -$0.35 | -$0.35 | Met |
| EPS (GAAP) | – | – | – | -$1.37 | – | |
| FCF | -$16.9 Million | – | – | -$75.6 Million | – | – |
| Margins | ~ (10%) | – | – | – | – | – |
| Cash (on Hand) | $100.4 Million | – | – | $100.4 Million | – | – |
| Runway | ~ 18 months |
Significance
- The “Beat” that Matters: The -$0.01 Adjusted EPS was a massive surprise to the upside. It shows that management is running a much tighter ship during the commercial launch than the market had expected.
- Launch Velocity: $3.4 million of the Q4 revenue came from just two months of PAPZIMEOS (PRGN-2012) shipments. The “miss” on Q4 revenue estimates ($4.57M vs $8.29M) was largely due to overestimating how fast hospitals could process new billing codes, not a lack of demand.
- Guidance Momentum: Management is projecting $18M+ in revenue for Q1 2026, which would represent a near-doubling of their entire 2025 performance in just 90 days.
- EPS Discrepancy (GAAP vs non-GAAP): The massive GAAP net loss of $429.6 million ($1.37/share) includes $318.5 million in non-cash charges related to preferred stock warrants—management states that these are one-time charges and will not recur.
Key Growth Drivers
- PAPZIMEOS (PRGN-2012) Scaling: PGEN is on the brink of its first commercial launch with PRGN-2012. The “first-in-class” gene therapy for RRP (Recurrent Respiratory Papillomatosis) is now the primary revenue engine. With a 51% complete response rate in trials, it remains a “must-have” for patients and “cheaper” for the payers (Medicare etc.).
- Operational Efficiency: Stabilizing the quarterly cash burn at $16.9M while doubling revenue y/y is a rare feat for a scaling biotech.
Risks
- Negative Margins: At -10% gross margin, the company is still spending more to make the drug than they are receiving. This must flip positive by mid-2026 to hit their breakeven targets.
- Execution Friction: Any regulatory delay in their pediatric trials or international expansion could stretch that 18-month cash runway thin.
Bottom Line
PGEN has successfully “crossed the chasm” from a speculative lab to a commercial player. With a $100M war chest and 2026 revenue projected to dwarf 2025, the stock is no longer a bet on science—it’s a bet on sales execution.
